This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Aschele, C. Articles by Sobrero, A. Search for Related Content PubMed PubMed Citation Articles by Aschele, C. Articles by Sobrero, A. Social Bookmarking                            What's this?

Immunohistochemical Quantitation of Thymidylate Synthase Expression in Colorectal Cancer Metastases Predicts for Clinical Outcome to Fluorouracil-Based Chemotherapy

From the Department of Medical Oncology, Istituto Nazionale per la Ricerca sul Cancro, Genova, Department of Pathology, E.O. Ospedali Galliera, Genova, and University of Udine, Udine, Italy; and Wadsworth Center, New York State Department of Health, Albany, NY.

Address reprint requests to C. Aschele, MD, Divisione di Oncologia Medica, Azienda Ospedaliera di Padova, Via Giustiniani 2, 35128 Padova, Italy; email c.aschele{at}galliera.it 16132, Genova, Italy; email aschele@hp380.ist.unige.it.

PURPOSE: To determine whether immunohistochemical thymidylate synthase (TS) quantitation predicts for clinical outcome in patients with advanced colorectal cancer treated by fluorouracil (FUra)-based chemotherapy.

PATIENTS AND METHODS: TS levels were measured immunohistochemically on archival specimens of colorectal cancer metastases from 48 patients homogenously treated by bolus FUra plus methotrexate alternating with continuous-infusion FUra plus leucovorin. These measurements were retrospectively correlated with patient characteristics and clinical outcome.

RESULTS: A significant correlation was found between intratumoral TS expression and all the parameters of clinical outcome analyzed. In patients whose tumors had low (n = 27) and high (n = 21) TS levels, the overall response rates were 67% and 24%, respectively (P = .003). The percentage of tumor shrinkage after chemotherapy was linearly related to TS immunoreactivity (r = .56, P = .00004), and its mean values were 65% and 14% with low and high TS levels, respectively (P = .0001). By logistic regression analysis, low TS expression was the single best predictor of response to chemotherapy (relative probability, 5.0). In patients with low and high TS expression, the median time to progression was 9.6 months v 6.2 months (P = .005) and the median survival time 18.4 months v 15.4 months (P = .02), respectively. Two- and 3-year survival rates were 41% v 15% and 19% v 0% (P = .02), respectively.

CONCLUSION: In this cohort of homogenously treated patients, intratumor TS content was a major predictor of clinical outcome. Immunohistochemical TS quantitation provides a convenient, low-cost technique for identifying patients unresponsive to TS inhibitors who may be candidates for alternative chemotherapy regimens.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				M. W. Saif, A. Choma, S. J. Salamone, and E. Chu Pharmacokinetically Guided Dose Adjustment of 5-Fluorouracil: A Rational Approach to Improving Therapeutic Outcomes J Natl Cancer Inst, October 19, 2009; (2009) djp328v1. [Abstract] [Full Text] [PDF]

				L. R. Moreira, A. Almeida Schenka, P. Latuff Filho, H. Nascimento, C. S. Passos Lima, M. A. Silva Trevisan, and J. Vassallo Correlation Between Thymidylate Synthase Protein Expression and Gene Polymorphism with Clinicopathological Parameters in Colorectal Carcinoma International Journal of Surgical Pathology, June 1, 2009; 17(3): 181 - 186. [Abstract] [PDF]

				R. Sharma, J. M. Hoskins, L. P. Rivory, M. Zucknick, R. London, C. Liddle, and S. J. Clarke Thymidylate Synthase and Methylenetetrahydrofolate Reductase Gene Polymorphisms and Toxicity to Capecitabine in Advanced Colorectal Cancer Patients Clin. Cancer Res., February 1, 2008; 14(3): 817 - 825. [Abstract] [Full Text] [PDF]

				P. Seve, R. Lai, K. Ding, T. Winton, C. Butts, J. Mackey, C. Dumontet, L. Dabbagh, S. Aviel-Ronen, L. Seymour, et al. Class III {beta}-Tubulin Expression and Benefit from Adjuvant Cisplatin/Vinorelbine Chemotherapy in Operable Non-Small Cell Lung Cancer: Analysis of NCIC JBR.10 Clin. Cancer Res., February 1, 2007; 13(3): 994 - 999. [Abstract] [Full Text] [PDF]

				J.-H. Lee, J.-H. Park, Y. Jung, J.-H. Kim, H.-S. Jong, T.-Y. Kim, and Y.-J. Bang Histone deacetylase inhibitor enhances 5-fluorouracil cytotoxicity by down-regulating thymidylate synthase in human cancer cells Mol. Cancer Ther., December 1, 2006; 5(12): 3085 - 3095. [Abstract] [Full Text] [PDF]

				V. Garcia, J. M. Garcia, C. Pena, J. Silva, G. Dominguez, A. Hurtado, I. Alonso, R. Rodriguez, M. Provencio, and F. Bonilla Thymidylate synthase messenger RNA expression in plasma from patients with colon cancer: prognostic potential. Clin. Cancer Res., April 1, 2006; 12(7): 2095 - 2100. [Abstract] [Full Text] [PDF]

				C. H. Smorenburg, G. J. Peters, C. J. van Groeningen, P. Noordhuis, K. Smid, A. M. G. H. van Riel, W. Dercksen, H. M. Pinedo, and G. Giaccone Phase II study of tailored chemotherapy for advanced colorectal cancer with either 5-fluouracil and leucovorin or oxaliplatin and irinotecan based on the expression of thymidylate synthase and dihydropyrimidine dehydrogenase Ann. Onc., January 1, 2006; 17(1): 35 - 42. [Abstract] [Full Text] [PDF]

				K. Ohrling, D. Edler, M. Hallstrom, P. Ragnhammar, and H. Blomgren Detection of Thymidylate Synthase Expression in Lymph Node Metastases of Colorectal Cancer Can Improve the Prognostic Information J. Clin. Oncol., August 20, 2005; 23(24): 5628 - 5634. [Abstract] [Full Text] [PDF]

				J. D. Ahlgren Thymidylate Synthase in Nodal Metastases: Prognostic for Chemosensitivity But Not for Adjuvant Therapy? J. Clin. Oncol., August 20, 2005; 23(24): 5452 - 5454. [Full Text] [PDF]

				B. M. Ghadimi, M. Grade, M. J. Difilippantonio, S. Varma, R. Simon, C. Montagna, L. Fuzesi, C. Langer, H. Becker, T. Liersch, et al. Effectiveness of Gene Expression Profiling for Response Prediction of Rectal Adenocarcinomas to Preoperative Chemoradiotherapy J. Clin. Oncol., March 20, 2005; 23(9): 1826 - 1838. [Abstract] [Full Text] [PDF]

				D. J. Sargent, B. A. Conley, C. Allegra, and L. Collette Clinical Trial Designs for Predictive Marker Validation in Cancer Treatment Trials J. Clin. Oncol., March 20, 2005; 23(9): 2020 - 2027. [Abstract] [Full Text] [PDF]

				S. Kamoshida, H. Matsuoka, T. Ishikawa, K. Maeda, R. Shimomura, K.-i. Inada, and Y. Tsutsumi Immunohistochemical Evaluation of Thymidylate Synthase (TS) and p16INK4a in Advanced Colorectal Cancer: Implication of TS Expression in 5-FU-based Adjuvant Chemotherapy Jpn. J. Clin. Oncol., October 1, 2004; 34(10): 594 - 601. [Abstract] [Full Text] [PDF]

				C. Aschele, D. Debernardis, S. Lonardi, R. Bandelloni, S. Casazza, S. Monfardini, and L. Gallo Deleted in Colon Cancer Protein Expression in Colorectal Cancer Metastases: A Major Predictor of Survival in Patients With Unresectable Metastatic Disease Receiving Palliative Fluorouracil-Based Chemotherapy J. Clin. Oncol., September 15, 2004; 22(18): 3758 - 3765. [Abstract] [Full Text] [PDF]

				T. Lecomte, J.-M. Ferraz, F. Zinzindohoue, M.-A. Loriot, D.-A. Tregouet, B. Landi, A. Berger, P.-H. Cugnenc, R. Jian, P. Beaune, et al. Thymidylate Synthase Gene Polymorphism Predicts Toxicity in Colorectal Cancer Patients Receiving 5-Fluorouracil-based Chemotherapy Clin. Cancer Res., September 1, 2004; 10(17): 5880 - 5888. [Abstract] [Full Text] [PDF]

				K.-H. Chi, H.-E. Wang, Y.-S. Wang, S.-L. Chou, H.-M. Yu, Y.-H. Tseng, I.-M. Hwang, and W.-Y. Lui Antisense Thymidylate Synthase Electrogene Transfer to Increase Uptake of Radiolabeled Iododeoxyuridine in a Murine Model J. Nucl. Med., March 1, 2004; 45(3): 478 - 484. [Abstract] [Full Text]

				S. Popat, A. Matakidou, and R. S. Houlston Thymidylate Synthase Expression and Prognosis in Colorectal Cancer: A Systematic Review and Meta-Analysis J. Clin. Oncol., February 1, 2004; 22(3): 529 - 536. [Abstract] [Full Text] [PDF]

				O. Belvedere, F. Puglisi, C. Di Loreto, P. Cataldi, A. Guglielmi, C. Aschele, and A. Sobrero Lack of correlation between immunohistochemical expression of E2F-1, thymidylate synthase expression and clinical response to 5-fluorouracil in advanced colorectal cancer Ann. Onc., January 1, 2004; 15(1): 55 - 58. [Abstract] [Full Text] [PDF]

				J. Chen, D. J. Hunter, M. J. Stampfer, C. Kyte, W. Chan, J. G. Wetmur, R. Mosig, J. Selhub, and J. Ma Polymorphism in the Thymidylate Synthase Promoter Enhancer Region Modifies the Risk and Survival of Colorectal Cancer Cancer Epidemiol. Biomarkers Prev., October 1, 2003; 12(10): 958 - 962. [Abstract] [Full Text] [PDF]

				T. Tsuji, S. Hidaka, T. Sawai, T. Nakagoe, H. Yano, M. Haseba, H. Komatsu, H. Shindou, H. Fukuoka, M. Yoshinaga, et al. Polymorphism in the Thymidylate Synthase Promoter Enhancer Region Is Not an Efficacious Marker for Tumor Sensitivity to 5-Fluorouracil-based Oral Adjuvant Chemotherapy in Colorectal Cancer Clin. Cancer Res., September 1, 2003; 9(10): 3700 - 3704. [Abstract] [Full Text] [PDF]

				V. Cohen, V. Panet-Raymond, N. Sabbaghian, I. Morin, G. Batist, and R. Rozen Methylenetetrahydrofolate Reductase Polymorphism in Advanced Colorectal Cancer: A Novel Genomic Predictor of Clinical Response to Fluoropyrimidine-based Chemotherapy Clin. Cancer Res., May 1, 2003; 9(5): 1611 - 1615. [Abstract] [Full Text] [PDF]

				J. R. Bertino and D. Banerjee Is the Measurement of Thymidylate Synthase to Determine Suitability for Treatment with 5-Fluoropyrimidines Ready for Prime Time? Clin. Cancer Res., April 1, 2003; 9(4): 1235 - 1239. [Full Text] [PDF]

				C. Allegra and D. Sargent Molecular Diagnostics: Assays, Tissues, Progress, and Pitfalls J. Clin. Oncol., February 1, 2003; 21(3): 395 - 396. [Full Text] [PDF]

				M. Gonen, A. Hummer, A. Zervoudakis, D. Sullivan, Y. Fong, D. Banerjee, D. Klimstra, C. Cordon-Cardo, J. Bertino, and N. Kemeny Thymidylate Synthase Expression in Hepatic Tumors Is a Predictor of Survival and Progression in Patients With Resectable Metastatic Colorectal Cancer J. Clin. Oncol., February 1, 2003; 21(3): 406 - 412. [Abstract] [Full Text] [PDF]

				W. Ichikawa, H. Uetake, Y. Shirota, H. Yamada, N. Nishi, Z. Nihei, K. Sugihara, and R. Hirayama Combination of Dihydropyrimidine Dehydrogenase and Thymidylate Synthase Gene Expressions in Primary Tumors as Predictive Parameters for the Efficacy of Fluoropyrimidine-based Chemotherapy for Metastatic Colorectal Cancer Clin. Cancer Res., February 1, 2003; 9(2): 786 - 791. [Abstract] [Full Text] [PDF]

				C. J. Allegra, S. Paik, L. H. Colangelo, A. L. Parr, I. Kirsch, G. Kim, P. Klein, P. G. Johnston, N. Wolmark, and H. S. Wieand Prognostic Value of Thymidylate Synthase, Ki-67, and p53 in Patients With Dukes' B and C Colon Cancer: A National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project Collaborative Study J. Clin. Oncol., January 15, 2003; 21(2): 241 - 250. [Abstract] [Full Text] [PDF]

				C. Aschele, D. Debernardis, R. Bandelloni, S. Cascinu, V. Catalano, P. Giordani, S. Barni, D. Turci, G. Drudi, S. Lonardi, et al. Thymidylate synthase protein expression in colorectal cancer metastases predicts for clinical outcome to leucovorin-modulated bolus or infusional 5-fluorouracil but not methotrexate-modulated bolus 5-fluorouracil Ann. Onc., December 1, 2002; 13(12): 1882 - 1892. [Abstract] [Full Text] [PDF]

				D. Edler, B. Glimelius, M. Hallstrom, A. Jakobsen, P. G. Johnston, I. Magnusson, P. Ragnhammar, and H. Blomgren Thymidylate Synthase Expression in Colorectal Cancer: A Prognostic and Predictive Marker of Benefit From Adjuvant Fluorouracil-Based Chemotherapy J. Clin. Oncol., April 1, 2002; 20(7): 1721 - 1728. [Abstract] [Full Text] [PDF]

				E. Villafranca, Y. Okruzhnov, M. A. Dominguez, J. Garcia-Foncillas, I. Azinovic, E. Martinez, J. J. Illarramendi, F. Arias, R. Martinez-Monge, E. Salgado, et al. Polymorphisms of the Repeated Sequences in the Enhancer Region of the Thymidylate Synthase Gene Promoter May Predict Downstaging After Preoperative Chemoradiation in Rectal Cancer J. Clin. Oncol., March 15, 2001; 19(6): 1779 - 1786. [Abstract] [Full Text] [PDF]

				C. Aschele, D. Debernardis, G. Tunesi, F. Maley, and A. Sobrero Thymidylate Synthase Protein Expression in Primary Colorectal Cancer Compared with the Corresponding Distant Metastases and Relationship with the Clinical Response to 5-Fluorouracil Clin. Cancer Res., December 1, 2000; 6(12): 4797 - 4802. [Abstract] [Full Text]

				D. Banerjee, R. Gorlick, A. Liefshitz, K. Danenberg, P. C. Danenberg, P. V. Danenberg, D. Klimstra, S. Jhanwar, C. Cordon-Cardo, Y. Fong, et al. Levels of E2F-1 Expression Are Higher in Lung Metastasis of Colon Cancer As Compared with Hepatic Metastasis and Correlate with Levels of Thymidylate Synthase Cancer Res., May 1, 2000; 60(9): 2365 - 2367. [Abstract] [Full Text]

				D. Edler, M. Hallström, P. G. Johnston, I. Magnusson, P. Ragnhammar, and H. Blomgren Thymidylate Synthase Expression: An Independent Prognostic Factor for Local Recurrence, Distant Metastasis, Disease-free and Overall Survival in Rectal Cancer Clin. Cancer Res., April 1, 2000; 6(4): 1378 - 1384. [Abstract] [Full Text]